CN1031243C - Medicine for treatment of leukoderma - Google Patents

Medicine for treatment of leukoderma Download PDF

Info

Publication number
CN1031243C
CN1031243C CN 93106579 CN93106579A CN1031243C CN 1031243 C CN1031243 C CN 1031243C CN 93106579 CN93106579 CN 93106579 CN 93106579 A CN93106579 A CN 93106579A CN 1031243 C CN1031243 C CN 1031243C
Authority
CN
China
Prior art keywords
radix
medicine
fructus
polygoni multiflori
paeoniae alba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN 93106579
Other languages
Chinese (zh)
Other versions
CN1080862A (en
Inventor
郭念筠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN 93106579 priority Critical patent/CN1031243C/en
Publication of CN1080862A publication Critical patent/CN1080862A/en
Application granted granted Critical
Publication of CN1031243C publication Critical patent/CN1031243C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a medicine for treating leukoderma, which is made according to the method of nourishing livers and kidneys. The medicine is prepared from tens of medicines, such as milkvetch seed, glossy privet fruit, raspberry, fleece-flower root, black sesame, tribulus terrestris, angelica, chuanxiong rhizome, wolfberry fruit, raw prepared rhizome of rehmannia, red white peony root, cassia twig, nutagrass flatsedge rhizome and pearl barley. An oral medicine and an externally used medicine for treating leukoderma, which are prepared by the present invention, treat 5000 patients with the curing rate of 31%; the obvious effective rate is 40%, and the total effective rate is 98.4%.

Description

Treat leukodermic medicine
The present invention belongs to the dermopathic medicine of a kind of treatment, specifically relates to treat the dermopathic oral medicine of vitiligo, medicine for external use.
Vitiligo is to be the common clinical of cardinal symptom with the skin depigmentation, the leukodermic medicine of many treatments is arranged at present both at home and abroad, but still there is not the satisfied preparation that effects a permanent cure, the medicine that has also toxic side effect Chinese traditional treatment vitiligo in all age is many with wind, blood stasis argument, mostly the Chinese herbal medicine of institute's adapted is the medicine that takes stopgap measures with expelling wind and activating blood circulation, and some medicine for external use use the back to destroy too much suffering from leukodermic epidermis cell mostly, and skin is had different damages.
The objective of the invention is to be to provide a kind of medicine that has no side effect,, regulate immunologic function, reach and fundamentally treat vitiligo by nourishing the liver and kidney with prepared from traditional Chinese medicines
Another object of the present invention is to be to provide a kind of traditional Chinese medical science oral medicine, does not promptly damage illing skin, also can treat owing to immune dysfunction the caused all kinds of symptom of deficiency of the liver and kindey.
The 3rd purpose of the present invention is to be to provide a kind of large tracts of land patients with vitiligo is taken for a long time can treat vitiligo and the oral medicine useful to human body.
The 4th purpose of the present invention is to be to provide the Chinese herbal medicine for oral administration and the medicine of external, is the local affected part of protection vitiligo, makes it self produce black island ability, and avoided most of medicine for external use to destroy leukodermic epidermis cell, damage vitiligo and normal skin.
The invention reside in above-mentioned four kinds of purposes and provide a kind of can making to suffer from the medicine that leukodermic skin reverts to the normal colour of skin: to using other for oral administration, medicine for external use, the vitiligo of damaging skin has the inhibition diffusion.
The objective of the invention is to realize by following prepared from traditional Chinese medicines.
Feature of the present invention is to be raw material with the Chinese herbal medicine, and compatibility is altogether:
Every ball is the small honey pill of Semen Glycines size.
Two, capsule compound method:
Semen Astragali Complanati 100g Fructus Ligustri Lucidi 90g Fructus Rubi 90g Radix Polygoni Multiflori 100g Semen Sesami Nigrum 100g
Fructus Atriplicis Sibiricae 40g Radix Angelicae Sinensis 660g Rhizoma Chuanxiong 30g Fructus Lycii 90g
Give birth to the living Rhizoma Cyperi 30g of each 40g Ramulus Cinnamomi 30g of the red Radix Paeoniae Alba of each 40g of Radix Rehmanniae Preparata and fry Semen Coicis 60g
More than ten Six-elements soak, boil, carry, concentrate, be dried to dry extract and pulverize again, cross 2,000
Mesh sieve 2 times is sub-packed in the capsule, each pastille 0.4g.
Three, electuary compound method:
Semen Astragali Complanati 100g Fructus Ligustri Lucidi 100g Fructus Rubi 90g Radix Polygoni Multiflori 100g Semen Sesami Nigrum 100g
Fructus Atriplicis Sibiricae 40g Radix Angelicae Sinensis 60g Rhizoma Chuanxiong 30g Fructus Lycii 60g
Give birth to the living Rhizoma Cyperi 40g of each 30g Ramulus Cinnamomi 30g of the red Radix Paeoniae Alba of each 30g of Radix Rehmanniae Preparata and fry Semen Coicis 60g
More than ten Six-element medicines soak, boil, extract extract (1), recrement adds decocting in water, carries receiving and extracts
Thing (2), merge (1) (2) extracting solution concentrate drying become dry extract to pulverize again to add adjuvant (dextrin,
Boil and carry) granulate every bag of 12g of dry back packing.
Four, hot compressed drug compound method:
Semen Astragali Complanati 10g Fructus Ligustri Lucidi 10g Fructus Rubi 10g Radix Polygoni Multiflori 10g Semen Sesami Nigrum 10g
Fructus Atriplicis Sibiricae 10g Radix Angelicae Sinensis 10g Rhizoma Chuanxiong 10g Fructus Lycii 10g
Give birth to the living Rhizoma Cyperi 10g of each 6g Ramulus Cinnamomi 10g of the red Radix Paeoniae Alba of each 6g of Radix Rehmanniae Preparata and fry Semen Coicis 10g
More than ten Six-elements, two gauze bags of packing into, put into cold water and soaked 20 minutes, boil again and fry in shallow oil 20 minutes, place and be placed on the affected part hot compress when not scalding (about 50 ℃), a position requires 30 minutes, two gauzes are used alternatingly every day 1-2 time.Time spent can use the medicine reheat later on, and 1 pair of medicine can be used 2-4 days.
Five, the compound method of external-applied ointment:
Semen Astragali Complanati 100g Fructus Ligustri Lucidi 100g Fructus Rubi 60g Radix Polygoni Multiflori 100g Semen Sesami Nigrum 60g
Fructus Atriplicis Sibiricae 40g Radix Angelicae Sinensis 40g Rhizoma Chuanxiong 40g Fructus Lycii 40g
Give birth to the living Rhizoma Cyperi 40g of each 20g Ramulus Cinnamomi 40g of the red Radix Paeoniae Alba of each 20g of Radix Rehmanniae Preparata and fry Semen Coicis 40g
(1) Radix Angelicae Sinensis, Ramulus Cinnamomi, Rhizoma Chuanxiong add water steaming and decocting extraction volatile oil.
(2) surplus group medicine adds the water steaming and decocting and is concentrated into cream.
(3) get silicone oil 3550g, liquid paraffin 150g, hard ester acid 100g, 18-alcohol 40g, 16-alcohol 20g,
Azone 10g, glycerol 20g, face cream 10g, above composition and above-mentioned thick paste mix well, and be every
Day 2 times, spread on and suffer from the vitiligo place.
Six, press the compound method of agent:
Semen Astragali Complanati 20g Fructus Ligustri Lucidi 10g Fructus Rubi 10g Radix Polygoni Multiflori 20g Semen Sesami Nigrum 10g
Fructus Atriplicis Sibiricae 10g Radix Angelicae Sinensis 10g Rhizoma Chuanxiong 10g Fructus Lycii 10g
Give birth to the living Rhizoma Cyperi 10g of each 10g Ramulus Cinnamomi 10g of the red Radix Paeoniae Alba of each 10g of Radix Rehmanniae Preparata and fry Semen Coicis 10g
Ten Six-element medicines are cleaned, put in the pot with vinegar, be blended into proper amount of clear water, heated and boiled goes out juice.Sieved in pig iron end, remove clean impurity, fire was forged 50 minutes, poured medicine juice while hot into, stirred evenly airing, in the paper bag of packing into.Every day 3 times, each 1 bag.
Seven, the compound method of surperficial aerosol:
Semen Astragali Complanati 10g Fructus Ligustri Lucidi 10g Fructus Rubi 10g Radix Polygoni Multiflori 15g Semen Sesami Nigrum 10g
Fructus Atriplicis Sibiricae 6g Radix Angelicae Sinensis 10g Rhizoma Chuanxiong 6g Fructus Lycii 6g
Give birth to the living Rhizoma Cyperi 10g of each 6g Ramulus Cinnamomi 10g of the red Radix Paeoniae Alba of each 6g of Radix Rehmanniae Preparata and fry Semen Coicis 10g
The present invention carries out pathological observation to 20 examples wherein, the skin biopsy HE.FONTANA dyeing of treatment back, melanin is all positive, 20 examples are carried out the white macula center and are treated the front and back electron microscopic observation, treat the interior visible melanin granule of melanocyte, the stem floor cells that closes on, spine cell that the back forms, the nail fold microcirculation is observed, and the blood stasis state has clear improvement.Treatment 5,000 routine cure rates reach 31%, and obvious effective rate 40%, total effective rate are 98.4%.Nontoxic, the side effect of the present invention is taken for a long time and is had no adverse reaction, and body's immunity is had tangible promotion and regulating action.
Clinical and experimentation is reported
One, treat picture and observational technique:
500 examples are all made a definite diagnosis by the vitiligo diagnostic criteria.With Chinese herbal medicine of the present invention, during the treatment, original all the used Chinese and western drugses of stopping using.Periodic review hemogram (leukocyte before and after the treatment; Classification), every immune indexes/IgG.A.M; T subset lymphocyte count, T cell subsets, microcirculation, pathology, and inspection such as Electronic Speculum.
Two, physical data:
1. sex: in the 500 routine patients with vitiligo, male's 241 examples, women's 259 examples.
2. age: minimum 1 years old of age, the maximum 82 years old; 98 examples (accounting for 19.6%) below 10 years old; 10~20 years old, 125 examples (accounting for 25%); 20~35 years old, 172 examples (accounting for 34.4%); 35~50 years old, 73 examples (accounting for 14.6%); 50~82 years old, 32 examples (accounting for 6.4%).
3. the course of disease: the 500 routine courses of disease in 1 year with interior 198 examples (accounting for 39.6%); 1~5 year, 101 examples (accounting for 20.2); 5~10 years, 98 examples (accounting for 19.6%); 10~30 years, 73 examples (accounting for 14.6%); 30 examples more than 30 years (accounting for 6%).
4. skin lesion site distribution: the distribution at 500 routine skin lesion positions:
Table 1
The position Head and neck The breast abdominal part Lower back Extremity General of whole body
The example number 227 48 45 98 82
Percentage rate 45.4 9.6 9 19.6 16.4
5. course of treatment: the treatment shortest time is a two weeks, and maximum duration is 10 years, and average course of treatment is 3 months~1 year.
Three, control the furuncle method: Chinese herbal and crude drugs preparations of the present invention.Oral medicine: decoction, pill, electuary, capsule;
Medicine for external use: hot compressed drug, ointment, liquid medicine, press agent, spray.
Taboo: period in a medicine taboo food Carnis caprae seu ovis, Eriocheir sinensis, alepidote and spicy food
Four, therapeutic effect:
1, clinical efficacy: the criterion of therapeutical effect by new drug (Chinese medicine) treatment vitiligo clinical research guideline in 1988 formulation is a criterion, and evaluation result sees Table 2.
Table 2 500 routine clinical efficacies
Example number/effect Complete Produce effects Effectively Invalid Total effective rate
The example number 155 200 137 8 492
Percentage rate 31 40 27.4 1.6 98.4
Total institute of present domestic report air force therapy of combining Chinese and Western medicine vitiligo 200 examples, cure 42 examples and account for 21%, produce effects 79 examples account for 38%, invalid 17 examples, total effective rate 91.5%, the People's Hospital, Xinjiang adopt dimension doctor, doctor trained in Western medicine combined treatment effective percentage to reach 98%, cure rate 10%.Recovery from illness 155 examples account for 31% in our clinical observation 500 examples, and produce effects 200 examples account for 40%, and total effective rate 98.4%, 8 example is invalid, the white macula size with have or not treat before and after significant difference.Own control is observed we's treatment front and back immunologic function significant difference.
General Symptoms improvement situation sees Table 3 before and after the 500 example treatments.
Table 3
Symptom The xerostomia polydipsia Fidgety night sweat Waist and leg ache Little sleep disturbed by dreams Cardiopalmus is nervous Hectic fever is weak Headache and dizzy Stomachache abdominal distention Monophagia is eaten less Constipation Menoxenia Easy to catch cold Red tongue
Treat the precedent number 420 431 380 300 146 342 198 102 382 301 156 212 412
Treat the routine number in back Cure 98 130 100 92 56 101 56 31 110 178 67 110 52
Produce effects 121 201 183 112 36 121 78 43 98 101 50 61 250
Effectively 195 95 92 90 48 108 58 23 166 20 31 33 89
Invalid 6 5 5 6 6 12 6 5 8 4 8 6 14
Effective percentage 7 98.5 98.8 98.6 98 95 95 96 95 97.9 98 94 97 96
2, the microcirculatory observation of nail fold:
23 routine patient's blood capillary loop top blood stasis 18 examples (accounting for 78.26%); The venule stasis of blood is opened 16 examples (accounting for 69.57%); High-visible 12 examples of vascular plexus (accounting for 52.17%) under the nipple; Congested expansion 3 examples (accounting for 13.04%) show that patients with vitiligo, microcirculqtory system have slight blood stasis more.And little slow blood flow flow velocity at 5 seconds/0.3mm with interior person's 18 examples (accounting for 78.26%), above person's 3 examples of 5 seconds/0.3mm (accounting for 13.04%).Most of patients nail fold sweat gland hyperactivity 15 examples (68.22%).
Wherein compare observation before and after the 11 example treatments, after the treatment, loop top blood stasis has improver's 7 examples (accounting for 63.63%) (P=0.05); Visible person's 3 examples of vascular plexus (accounting for 27.27%) under the nipple, 1 example (XX=10.96 P<0.01) is not seen in congested expansion, and 5 seconds/0.3mm is with interior person's 5 examples (accounting for 45,45%) for treatment back blood flow rate, none example has surpassed 5 seconds/0.3mm, (X=9.25, P<0.01), treatment back nail fold sweat gland hyperactivity person 3 examples, (accounting for 27.27%) (XX=4.3 P<0.05), show the nourishing the liver and kidney method,, the nail fold of improvement microcirculation is arranged and adjust neuro vegetative effect patients with vitiligo.
3, pathologic finding:
Make illing skin biopsy controlled observation before and after the four routine patient treatments, treat last routine skin histology basic unit depigmentation, Fontana dyeing melanin feminine gender.There is a little melanin equal basal layer of epidermis of three examples and prickle cell layer subregion in addition.Treatment back four routine skin biopsy HE.FonHE.Fontana dyeing melanin are all positive.
4, electron microscopic observation:
Treating preceding 9 examples draws materials in the white macula center, transmission electron microscope observing, the equal broadening of basal layer and acantholysis cell gap, wherein do not see melanin granule fully in the 4 routine melanocytes, five examples only have micro-melanocyte in addition, still draw materials in former white macula place after the treatment, 3 routine basal layer of epidermis melanocytes are arranged closely, have a large amount of melanin granules to form in the dentritic cell.Visible melanin granule in matrix cells that melanocyte closes on and the spine cell, the melanosome that has is found in the shallow-layer of keratinocyte.Langerhans' cells does not have significant change before and after the treatment.
The electron microscopic observation explanation, melanin granule forms with it and has recovered normal in intraepidermal metabolic process in the melanocyte of treatment back white macula disappearance part.
5, immune indexes is observed:
(1) periphery blood T cell number
Looking into 169 patients has 126 examples (74.6%) T cell number to be lower than normal value 43 examples (25.4%), and normally none example is higher.
The periphery blood T cell number relatively before and after the table 4 80 routine patient treatments
T cell number (%) X+-SD The P value
Before the treatment 49.275+-9.541
After the treatment 60.718+-8.373 <0.001
(2) T cell subsets
The comparison of T cell subsets before and after the table 5 20 routine patient treatments
X+-SE (%) before the treatment Treatment back X+-SE (%) The P value
CD3 51.00+-2.41 45.95+-1.65 >0.05
CD4 28.68+-2.69 37.36+-0.93 <0.001
CD8 29.5+-1.41 27.0+-1.85 >0.05
CD4/CD8 1.03+-0.09 1.54+-0.15 <0.01
Treatment back T4 (P<0.001) T4/T8 ratio (P<0.01) (3) lymphproliferation response that also obviously raises that obviously raises
Lymphproliferation response result before and after table 67 routine patients treat
CPm value number (X+-SE) The P value
Before the treatment 3864.07+-902.79
After the treatment 6858.49+-1721.24 <0.01
(4) peripheral blood immunoglobulin content
Survey 169 routine patients, normal person's 145 examples of IgG (85.8%), low value person 24 examples (14.2%), normal 127 examples of IgA (75.2%), higher 2 examples (1.2%) low value 49 examples (23.6%), normal 101 examples of IgM (60%) low value 68 examples (40%), result show that the patients with vitiligo immunoglobulin part is on the low side
Ig content relatively before and after the table 7 80 routine patient treatments
Serum I g content (XISD) (mg/ml)
IgG IgA IgM
Before the treatment 11.44+-3.065 1.22+-0.45 0.488+-0.219
After the treatment 11.84+-3.104 1.39+-0.341 0.579+-0.315
The P value >0.05 <0.05 <0.05
All significantly risings of treatment back patient's serum IgA and IgM (the P value all<0.05)
(5) peripheral blood leucocyte phagocytic function:
Surveying patient's 18 routine CPM peak values (X+-SE) is 10484.6+-3411.87, and normal person's 9 examples are 21617.3+-8510.74, P value>0.05, no significant difference.
The peripheral blood leucocyte phagocytic function relatively before and after the table 87 routine patient treatments
CL peak value (X+-SE) CPM value The P value
Before the treatment 11139.28+-5246.9
After the treatment 45626.00+-318.594 <0.001
Treatment back patient's leukocyte chemiluminescence experiment CPM value is rising (P<0.001) (6) animal data A purpose obviously: by in vivo test, observe " increasing the side of exempting from " spleen antibody forming cell, the influence of spleen T lymphopoiesis function and peripheral blood leucocyte phagocytic function to white mice.B result: 30 mice hemolysis plaques of a. administration group number is (X+-SE) 1360+-58, and matched group is
1120+-55 (P<0.05), showing has the effect that promotes specific antibody to form cell.
B. 29 mouse lymphocyte conversion tests of administration group CPM value (X+-SE): 5179+-676;
Matched group is 3298+-617 (P<0.001), illustrates that COnA stimulates after the administration to cause
The T lymphproliferation response obviously raise.
C. 22 mice peripheral blood leucocyte of administration group chemiluminescence reaction is compared with matched group
No significant difference (P>0.05).

Claims (2)

  1. One, the leukodermic medicine of a kind of treatment is characterized in that it is by following raw material and weight processing formulated (in crude drug weight) thereof: Semen Astragali Complanati 10--100g Fructus Ligustri Lucidi 10--100g Fructus Rubi 10--100g Radix Polygoni Multiflori 10--100g Semen Sesami Nigrum 10--100g Fructus Atriplicis Sibiricae 10--60g Radix Angelicae Sinensis 10-60g Rhizoma Chuanxiong 10--50g Fructus Lycii 10--100g Radix Rehmanniae 10--60g Radix Rehmanniae Preparata 10--60g Radix Paeoniae Rubra 10--60g Radix Paeoniae Alba 10--60g Ramulus Cinnamomi 10--60g Rhizoma Cyperi 10--50g Semen Coicis 10--60g
  2. Two, according to the medicine of claim one, Rhizoma Cyperi wherein is living Rhizoma Cyperi, and the Radix Paeoniae Alba is a Radix Paeoniae Alba (parched), and the Radix Polygoni Multiflori is a Radix Polygoni Multiflori Preparata, and Radix Angelicae Sinensis is a Radix Angelicae Sinensis.
    Semen Astragali Complanati: 10-100g Fructus Ligustri Lucidi: 10-100g Fructus Rubi: 10-100g
    Radix Polygoni Multiflori: 10-100g Semen Sesami Nigrum: 10-100g Fructus Atriplicis Sibiricae: 10-60g
    Radix Angelicae Sinensis: 10-60g Rhizoma Chuanxiong: 10-50g Fructus Lycii: 10-100g
    Give birth to Radix Rehmanniae Preparata: each red Radix Paeoniae Alba of 10-60g: each 10-60g Ramulus Cinnamomi: 10-60g
    Rhizoma Cyperi: 10-50g Semen Coicis: 10-60g
    Trailing plants, washing, oven dry, pulverizing are selected, crossed to above-mentioned tens kinds of Chinese herbal medicine, preparation in the desired amount, and powder, the molding pill is dried again, is pill for oral administration.
    Blended Chinese medicine, the Radix Paeoniae Alba are Radix Paeoniae Alba (parched), and the Radix Polygoni Multiflori is a Radix Polygoni Multiflori Preparata, and when being classified as Radix Angelicae Sinensis, Rhizoma Cyperi is living Rhizoma Cyperi.
    The present invention treats the made pill of leukodermic medicine, electuary, cream, presses agent etc., and curative effect is reliable, and no pain has no side effect, and welcome by extensive patients.
    The present invention began from 1971 5,000 example treatments, and cure rate reaches 31%, and obvious effective rate reaches 40%, and total effective rate reaches 98.4%.Be further to inquire into this side's mechanism of action, we quote a few deficiency of YIN animal models of first, observed should the side immune pharmacological action.This experimental result shows: all can make the model mice cellular immune function be adjusted to normal level through giving big or small two dosage Chinese herbal and crude drugs preparations of the present invention, heavy dose of effect is more obvious, two dose drugs have obvious regulating action to the model mice humoral immune function, result and clinical experiment basically identical.The morphologic observation of this experiment ultra micro, the impaired plasma cell form of model mice is recovered, can be improved the tissue morphology of spleen macrophage, increase the number of macrophage, also can increase the dendritic cell between the lymphocyte, zoopery proves that also we have no side effect.One, pill compound method:
    Semen Astragali Complanati 100g Fructus Ligustri Lucidi 80g Fructus Rubi 80g Radix Polygoni Multiflori 100g Semen Sesami Nigrum 100g
    Fructus Atriplicis Sibiricae 50g Radix Angelicae Sinensis 60g Rhizoma Chuanxiong 30g Fructus Lycii 90g
    Give birth to the living Rhizoma Cyperi 30g of each 30g Ramulus Cinnamomi 30g of the red Radix Paeoniae Alba of each 30g of Radix Rehmanniae Preparata and fry Semen Coicis 60g
    More than tens the flavor medicated powder be broken into fine powder, the mixing that sieves, every 100g powder adds refined honey 100g, makes
CN 93106579 1993-06-05 1993-06-05 Medicine for treatment of leukoderma Expired - Fee Related CN1031243C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 93106579 CN1031243C (en) 1993-06-05 1993-06-05 Medicine for treatment of leukoderma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 93106579 CN1031243C (en) 1993-06-05 1993-06-05 Medicine for treatment of leukoderma

Publications (2)

Publication Number Publication Date
CN1080862A CN1080862A (en) 1994-01-19
CN1031243C true CN1031243C (en) 1996-03-13

Family

ID=4986297

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 93106579 Expired - Fee Related CN1031243C (en) 1993-06-05 1993-06-05 Medicine for treatment of leukoderma

Country Status (1)

Country Link
CN (1) CN1031243C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101028375B (en) * 2007-04-04 2010-09-08 李春玲 Oral externally-applied Chinese medicinal composition for treating leucoderma
CN101637512B (en) * 2009-09-11 2011-09-28 刁保忠 Traditional Chinese medicine preparation for treating vitiligo

Also Published As

Publication number Publication date
CN1080862A (en) 1994-01-19

Similar Documents

Publication Publication Date Title
CN101987123B (en) Medicament for easing pain of human body and preparation method thereof
CN101987122B (en) Medicament for easing pain of human body and preparation method thereof
CN101732683A (en) Chinese medicinal preparation for treating facial chloasma and preparation method thereof
CN1162171C (en) Gynopathy treating traditional Chinese medicine
CN105106852A (en) Traditional Chinese medicine preparation for treating hyperplasia of mammary glands and breast cancer
CN108969642A (en) A kind of Chinese medicine compound prescription external preparation that treating chronic prostatitis and its preparation process
CN102727779B (en) Pharmaceutical composition for treating ovarian cysts and preparation method thereof
CN104258292A (en) Drug for department of obstetrics and gynecology for treating pregnancy complication and manufacturing method thereof
CN102357227A (en) Chinese medicinal composition for treating qi stagnation and blood stasis amenorrhea
CN1031243C (en) Medicine for treatment of leukoderma
CN1351872A (en) Chinese herbal medicine for curing comedo and acne
CN102204978B (en) Medicinal composition for treating cancer pain and preparation thereof
CN101518607B (en) Traditional Chinese medicine for treating carcinoma of kidney
CN1204908C (en) Deafness and tinnitus treating Chinese medicine and its prepn
CN110840861A (en) Cervical vertebra plaster formula for clearing and activating channels and collaterals and preparation method of plaster of cervical vertebra plaster formula
CN104352775A (en) Medicine for treating angina pectoris of coronary atherosclerotic heart disease
CN1086132C (en) Traditional Chinese medicinal pill for transforming calculus, eliminating toxin and anti tumour
CN1768846A (en) Chinese medicinal formulation for activating blood circulation, stopping pain and adjusting chemical balance
CN1201811C (en) Chinese medicine composition for treating myopia and preparing method thereof
CN102846910A (en) Chinese medicine preparation for the treatment of heart premature contraction
CN103007236B (en) Chinese medicinal composition for treating ankylosing spondylitis
CN103006995B (en) Medicine for treating post-dural puncture headache (PDPHA)
CN1309412C (en) Medicine composition for treating AIDS and preparing method thereof
CN1127968C (en) Oral powder medicine Xiaobaisan for treating leukotrichia and its preparation method
CN1504231A (en) Medicine for tumour

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Guo Nianjun

Document name: payment instructions

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee